New EU Template for QP Declaration (IMPs)
The European Commission has published a draft template for the Qualified Person's (QP) declaration concerning GMP compliance of investigational medicinal products (IMPs) manufactured in non-EU countries. The template would be part of the dossier submitted with a request for authorisation of a clinical trial.
In this template, the QP should confirm that the IMP manufactured in a third country meets EU GMP standards for IMPs. This could be proved by either a personal on-site audit or an audit conducted by a third party or by another QP employed by the importer. If no audit has been performed, a brief justification and explanation should be provided, describing how the QP knows that standards at least equivalent to EU GMP are being followed at the site.
Stakeholders are invited to comment on this draft by 2 April 2013. Responses should be sent preferably by e-mail to sanco-pharmaceuticals-d6@ec.europa.eu.
Related GMP News
05.09.2024Clinical Trials Regulation - Version 6.9 of the Q&As
23.07.2024Pilot Results on Regulatory-Led RWE Generation
23.07.2024ICH M12 Guideline on Drug Interaction Studies
20.06.2024Draft ICH M14 Guideline on Real-World Data for Safety Assessment
20.06.2024Glossary of Terms and Definitions for Innovative Clinical Trials
21.05.2024Real-World Evidence: FDA´s Considerations for Non-Interventional Studies